H.C. Wainwright raised the firm’s price target on ANI Pharmaceuticals to $83 from $73 and keeps a Buy rating on the shares following the Q4 beat. The firm says the company has momentum across its rare disease and generics units.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ANIP:
- ANI Pharmaceuticals price target raised to $80 from $72 at Truist
- ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance
- ANI Pharmaceuticals sees FY24 adjusted EPS $4.26-$4.67, consensus $4.33
- ANI Pharmaceuticals reports Q4 adjusted EPS $1.00, consensus 85c
- Is ANIP a Buy, Before Earnings?
